Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stress pills may reveal why you crave cannabis

NCT ID NCT06430580

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This study gives people with Cannabis Use Disorder drugs that mimic stress to see how it affects their desire for cannabis. Researchers measure brain activity and decision-making during four lab visits. The goal is to understand the link between stress and cannabis use motivation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hydrocortisone and Yohimbine Hydrochloride
What this could lead to
If successful, this could help explain how stress triggers cannabis cravings, pointing toward better treatments for Cannabis Use Disorder.
What could go wrong
This is a very early, small study (36 people) testing temporary stress-like effects, not a treatment. Results may not lead to real-world therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

38 people

The number who actually took part.

Started

Sep 2024

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meets criteria for current, moderate to severe Cannabis Use Disorder (CUD) as assessed by the Structured Clinical Interview (SCID) for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) during the screening interview. * Reports engagement in near-daily/daily cannabis use. * Provide a urine sample positive for THC. * Must be in generally good health as determined by a physical exam, EKG, and blood tests * Must be adequately informed of the nature and risks of the study and given written informed consent prior to screening. * Able to read and write in English. Exclusion Criteria: * Has a history of serious psychiatric problems (i.e., psychosis, Bipolar Disorder I) or meets criteria for a current Major Depressive Episode, as assessed by the SCID-V-RV. * Reports current suicidal ideation. * Meets DSM-5 criteria for any other current, moderate to severe substance use disorder (other than CUD or Tobacco Use Disorder * Has a positive result urine drug screen for all other drugs aside from THC (i.e., amphetamine, methamphetamine, benzodiazepine, cocaine, MDMA, morphine, oxycodone, methadone, buprenorphine) at screening or at any lab visit. * Has structural brain abnormalities (e.g., neoplasms), stroke, seizures, infectious disease, a history of other neurological diseases, or a history of head trauma resulting in unconsciousness. * Has a history of cardiovascular disease, myocardial infarction, chest pain, or palpitations on exertion or drug use, edema, hypertension, resting heart rate \<50 BPM or \>100 BPM. Cardiovascular diseases include: . a. Benign prostatic hyperplasia (BPH) b. Post-myocardial infarction * Demonstrates systolic BP outside of acceptable range (80-140mmHG), or diastolic BP outside of acceptable range (50-90 mmHG) * Has a history of cor pulmonale, dyspnea, orthopnea, tachypnea (\>24 breaths per minute), or uncontrolled chronic obstructive pulmonary disease or asthma. * Currently taking any daily psychotropic medication * Currently taking any of the following medications: 1. Angiotensin-Converting Enzyme (ACE) inhibitors including Lisinopril, Enalapril, Benazepril, and Bamipril 2. Angiotensin II Receptor Blockers (ARB) including Losartan, Valsartan, and Olmesartan 3. Thiazide Diuretics including Hydrochlorothiazide (HCTZ), Chlorthalidone 4. Calcium Channel Blockers including Amlodipine, Diltiazem, and Verapamil 5. Beta-blockers including Carvedilol, Metoprolol, Atenolol, Propranolol 6. Anti-Arrythmic Medication including Disopyramide, Flecainide, and Mexiletine 7. Edema (Diuretics) 8. Thiazide Diuretics (as above) 9. Loop Diuretics including Furosemide and Torsemide 10. Potassium Sparing Diuretics: Spironolactone and Eplerenone 11. Anti-Platelet Medications such as Clopidogrel, Prasugrel, and Ticagrelor * Reproductively capable candidates who are pregnant (based on urine test at screening or at any lab visit) or are heterosexually active and not using medically approved birth control measures (oral contraceptives, IUD, condom, sterilization). * Self-reports currently seeking or engaging in CUD treatment or any other alcohol or drug treatment. * Self-reports intent to imminently quit cannabis use. * Has a Blood-Injection-Injury Phobia, as determined by scores greater than 15 on the Injection and Blood Draw subscale of the Medical Fear Survey

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The BRAINS Lab at Florida State University

    Tallahassee, Florida, 32306-4301, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.